Cited by 901Cardiac Ischemia and ReperfusionDiabetes Treatment and ManagementAcute Myocardial Infarction Research

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, Lazaros A., Mankad, Sunil, Sokos, George G., Miske, Glen, Shah, Ankur, Elahi, Dariush, Shannon, Richard P.·2004·Circulation

DOI 10.1161/01.cir.0000120505.91348.58

Open this paper in CoChat — free account

Abstract

Background— Glucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion. Methods and Results— We investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients. Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion. Baseline demographics and background therapy were similar, and both groups had severe LV dysfunction at baseline (LVEF=29±2%). GLP-1 significantly improved LVEF (from 29±2% to 39±2%, P <0.01), global wall motion score indexes (1.94±0.11→1.63±0.09, P <0.01), and regional wall motion score indexes (2.53±0.08→2.02±0.11, P <0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects. Conclusions— When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000120505.91348.58

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year
Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils
Leaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605
Glucagon-Like Peptides
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598
Metabolic Modulation of Acute Myocardial Infarction
Díaz, R., Paolasso, E., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J., Romero, G., & Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction
van der Horst, I. C. C., Zijlstra, F., Hof, A. W. J. V. ’., Doggen, C. J. M., de Boer, M., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 259
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships
Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207
Insulin therapy as an adjunct toreperfusion after acute coronary ischemia
Sack, M. N., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00164-5 · Cited by 105
Glucose-Insulin-Potassium for Acute Myocardial Infarction
Apstein, C. S. (1998) · Circulation · doi:10.1161/01.cir.98.21.2223 · Cited by 95

Show all 15 references

Research works printed but not linked: 4

10.1161/circ.96.4.1074 · DOI
10.1161/circ.98.21.2227 · DOI
10.1161/circ.98.21.2223 · DOI
1987, Am Heart J, 102, 1038

Sorted by citations

Items 201–300 of 899

Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
Opie, L. H. (2008) · Circulation · doi:10.1161/circulationaha.108.780999 · Cited by 70
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options
Caterina, R. D., Madonna, R., Sourij, H., & Wascher, T. C. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq162 · Cited by 70
Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 68
Oral Administration of Corn Zein Hydrolysate Stimulates GLP-1 and GIP Secretion and Improves Glucose Tolerance in Male Normal Rats and Goto-Kakizaki Rats
Higuchi, N., Hira, T., Yamada, N., & Hara, H. (2013) · Endocrinology · doi:10.1210/en.2012-2275 · Cited by 69
Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus
Hulst, A. H., Polderman, J. A. W., Siegelaar, S. E., van Raalte, D. H., DeVries, J. H., Preckel, B., & Hermanides, J. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.10.023 · Cited by 70
Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
Lim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 70
DPP‐4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes
Connelly, K. A., Zhang, Y., Advani, A., Advani, S. L., Thai, K., Yuen, D. A., & Gilbert, R. E. (2012) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12005 · Cited by 67
Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus
Langley, A., Suffoletta, T. J., & Jennings, H. R. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1163 · Cited by 65
Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 68
Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix
Robinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S. M., Calderwood, D., Church, R. H., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 71
Cardiovascular impact of drugs used in the treatment of diabetes
Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 67
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
Russell, S. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9729-9 · Cited by 68
Myocardial Metabolism in Heart Failure
Ng, S. M., Neubauer, S., & Rider, O. J. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00589-y · Cited by 67
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
Liu, Q., Adams, L. A., Broyde, A., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.010 · Cited by 69
GLP-1 receptor agonists and heart failure in diabetes
Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30068-x · Cited by 65
Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury
Matheeussen, V., Jungraithmayr, W., & Meester, I. D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.012 · Cited by 66
Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia–reperfusion rat heart
Chinda, K., Sanit, J., Chattipakorn, S. C., & Chattipakorn, N. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113516134 · Cited by 66
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 67
Bariatric surgery as a treatment for heart failure: review of the literature and potential mechanisms
Kindel, T. L., & Strande, J. L. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.09.534 · Cited by 64
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 65
The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities
Rotkvić, P. G., Planinić, Z., Pršo, A.-M. L., Šikić, J., Galić, E., & Rotkvić, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115973 · Cited by 64
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
FESC, F. E. O. A. D.-4. I. O. L. V. D. D. I. P. W. T. 2. D. A. D. C. (. S. I., Oe, H., Nakamura, K., Kihara, H., Shimada, K., Fukuda, S., Takagi, T., Miyoshi, T., Hirata, K., Yoshikawa, J., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0242-z · Cited by 63
Diabetic cardiomyopathy: signaling defects and therapeutic approaches
Dobrin, J. S., & Lebeche, D. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.17 · Cited by 63
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 63
Heart Failure and Loss of Metabolic Control
Wang, Z. V., Li, D. ‘., & Hill, J. A. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000054 · Cited by 63
Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors
Chrysant, S. G., & Chrysant, G. S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.398 · Cited by 65
Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials
Mannucci, E., Dicembrini, I., Nreu, B., & Monami, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13888 · Cited by 62
Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium
DeNicola, M., Du, J., Wang, Z., Yano, N., Zhang, L., Wang, Y., Qin, G., Zhuang, S., & Zhao, T. C. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00109.2014 · Cited by 63
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus
O’Keefe, J. H., Abuannadi, M., Lavie, C. J., & Bell, D. S. H. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0434 · Cited by 62
Stress-induced hyperglycaemia in non-diabetic patients with acute coronary syndrome: from molecular mechanisms to new therapeutic perspectives
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion
Ku, H.-C., Chen, W., & Su, M. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0665-3 · Cited by 61
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 62
Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
McCormick, L. M., Kydd, A. C., Read, P. A., Ring, L. S., Bond, S. J., Hoole, S. P., & Dutka, D. P. (2014) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.113.000785 · Cited by 59
Incretin‐based therapies
Stonehouse, A. H., Darsow, T., & Maggs, D. G. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00143.x · Cited by 65
Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus
STOLAR, M. W. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0471 · Cited by 60
Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
Aravindhan, K., Bao, W., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130894 · Cited by 61
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Panchapakesan, U., Mather, A., & Pollock, C. A. (2012) · Clinical Science · doi:10.1042/cs20120167 · Cited by 57
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 61
Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
Circulating mediators of remote ischemic preconditioning: search for the missing link between non-lethal ischemia and cardioprotection
Billah, M., Ridiandries, A., Allahwala, U. K., Mudaliar, H., Dona, A. C., Hunyor, S. N., Khachigian, L. M., & Bhindi, R. (2019) · Oncotarget · doi:10.18632/oncotarget.26537 · Cited by 58
Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients
Starčević, J. N., Janić, M., & Šabović, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051197 · Cited by 59
Debate on Insulin vs Non-insulin Use in the Hospital Setting—Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?
Pasquel, F. J., Fayfman, M., & Umpierrez, G. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1184-8 · Cited by 56
Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Investigation of the haemodynamic effects of exenatide in healthy male subjects
Mendis, B., Simpson, E., MacDonald, I., & Mansell, P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04214.x · Cited by 56
Progression in attenuating myocardial reperfusion injury: An overview
Bernink, F. J. P., Timmers, L., Beek, A. M., Diamant, M., Roos, S. T., van Rossum, A. C., & Appelman, Y. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.007 · Cited by 56
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
Mannucci, E., & Rotella, C. M. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.08.002 · Cited by 57
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U. L., Holst, J. J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
GLP-1R agonist therapy for diabetes: benefits and potential risks
Samson, S. L., & Garber, A. (2013) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32835edb32 · Cited by 55
The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Paul, S. K., Klein, K., Maggs, D. G., & Best, J. H. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0178-3 · Cited by 56
Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization
McCormick, L. M., Hoole, S. P., White, P. A., Read, P. A., Axell, R. G., Clarke, S. J., O’Sullivan, M., West, N. E. J., & Dutka, D. P. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.09.014 · Cited by 55
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 55
Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits
Sudo, M., Li, Y., Hiro, T., Takayama, T., Mitsumata, M., Shiomi, M., Sugitani, M., Matsumoto, T., Hao, H., & Hirayama, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.920 · Cited by 54
Drug repurposing in kidney disease
Panchapakesan, U., & Pollock, C. A. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.026 · Cited by 56
Single Dose GLP-1-Tf Ameliorates Myocardial Ischemia/Reperfusion Injury
Matsubara, M., Kanemoto, S., Leshnower, B. G., Albone, E. F., Hinmon, R., Plappert, T. A., Gorman, J. H., & Gorman, R. C. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.03.016 · Cited by 54
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
Kumarathurai, P., Anholm, C., Nielsen, O. W., Kristiansen, O. P., Mølvig, J., Madsbad, S., Haugaard, S. B., & Sajadieh, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0425-2 · Cited by 54
Predictive Value of Plasma Glucose Level on Admission for Short and Long Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
Hoebers, L. P. C., Damman, P., Claessen, B. E. P. M., Vis, M. M., Baan, J., van Straalen, J. P., Fischer, J., Koch, K. T., Tijssen, J. G. P., de Winter, R. J., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.07.067 · Cited by 54
The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Incretin-Based Drugs and the Risk of Congestive Heart Failure
Yu, O. H. Y., Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., & Suissa, S. (2014) · Diabetes Care · doi:10.2337/dc14-1459 · Cited by 52
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 51
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
Fisman, E. Z., & Tenenbaum, A. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-38 · Cited by 52
No benefit of additional treatment with exenatide in patients with an acute myocardial infarction
Roos, S. T., Timmers, L., Biesbroek, P. S., Nijveldt, R., Kamp, O., van Rossum, A. C., van Hout, G. P. J., Stella, P. R., Doevendans, P. A., Knaapen, P., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.283 · Cited by 52
The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9–36)a in an isolated rat heart
Ossum, A. M., van Deurs, U., Engstrøm, T., Jensen, J. S., & Treiman, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.06.004 · Cited by 51
Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Ceccarelli, E., Guarino, E., Merlotti, D., Patti, A., Gennari, L., Nuti, R., & Dotta, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00073 · Cited by 51
Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus
Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0365-x · Cited by 51
Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study
Faber, R., Zander, M., Peña, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 52
Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome
Vergès, B. L., Avignon, A., Bonnet, F., Catargi, B., Cattan, S., Cosson, E., Ducrocq, G., Elbaz, M., Fredenrich, A., Gourdy, P., et al. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.003 · Cited by 51
Glucagon‐like Peptide‐1 and Myocardial Protection: More than Glycemic Control
Fields, A. V., Patterson, B., Karnik, A. A., & Shannon, R. P. (2009) · Clinical Cardiology · doi:10.1002/clc.20456 · Cited by 50
Self-citation
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Bao, W., Holt, L. J., Prince, R. D., Jones, G. X., Aravindhan, K., Szapacs, M., Barbour, A., Jolivette, L. J., Lepore, J. J., Willette, R. N., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-148 · Cited by 50
Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes
Lee, H. M., Joo, B. S., Lee, C. H., Kim, H. Y., Ock, J. H., & Lee, Y. S. (2015) · Journal of Menopausal Medicine · doi:10.6118/jmm.2015.21.2.93 · Cited by 50
Molecular aspects of ischaemic postconditioning
Kaur, S., Jaggi, A. S., & Singh, N. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00733.x · Cited by 49
Liraglutide Enhances Insulin Sensitivity by Activating AMP-Activated Protein Kinase in Male Wistar Rats
Yamazaki, S., Satoh, H., & Watanabe, T. (2014) · Endocrinology · doi:10.1210/en.2013-2157 · Cited by 49
In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes
Vis, M. M., Sjauw, K. D., van der Schaaf, R. J., Baan, J., Koch, K. T., DeVries, J. H., Tijssen, J. G. P., de Winter, R. J., Piek, J. J., & Henriques, J. P. S. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.028 · Cited by 49
Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?
Umpierrez, G. E., & Korytkowski, M. (2013) · Diabetes Care · doi:10.2337/dc12-2233 · Cited by 49
GLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Cosentino, F., Verma, S., Ambery, P., Treppendahl, M. B., van Eickels, M., Anker, S. D., Cecchini, M., Fioretto, P., Groop, P., Hess, D. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad445 · Cited by 66
Unique roles of glucagon and glucagon-like peptides: Parallels in understanding the functions of adipokinetic hormones in stress responses in insects
Bednářová, A., Kodrı́k, D., & Krishnan, N. (2012) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2012.10.012 · Cited by 48
Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway
Xiao, Y., Nikolskaya, A. V., Jaye, D. A., & Sigg, D. C. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-6 · Cited by 49
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
DPP4 Deficiency Exerts Protective Effect against H2O2 Induced Oxidative Stress in Isolated Cardiomyocytes
Ku, H.-C., Chen, W., & Su, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054518 · Cited by 49
Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
Li, J., Zheng, J., Wang, S., Lau, H., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 48
Role of postprandial hyperglycemia in cardiovascular disease
Fava, S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.6.859 · Cited by 47
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 47
GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction
Margulies, K. B., Anstrom, K. J., Hernandez, A. F., Redfield, M. M., Shah, M., Braunwald, E., & Cappola, T. P. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.000346 · Cited by 47
Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes
van Genugten, R. E., Möller-Goede, D. L., van Raalte, D. H., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12050 · Cited by 46
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Christensen, M., & Knop, F. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0102-x · Cited by 46
Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia.
Huisamen, B., Genade, S., & Lochner, A. (2008) · Europe PMC (PubMed Central) · Cited by 46
Direct cardiovascular effects of glucagon like peptide-1
Sheikh, A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-47 · Cited by 45
Glucagon-like Peptide-1 (GLP-1) and Protective Effects in Cardiovascular Disease: A New Therapeutic Approach for Myocardial Protection
Zhao, T. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-90 · Cited by 45
Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review
Dragonieri, S., Portacci, A., Quaranta, V. N., Carratù, P., Lázár, Z., Carpagnano, G. E., & Bikov, A. (2024) · Diseases · doi:10.3390/diseases12090224 · Cited by 49
Management of Hyperglycemia with the Administration of Intravenous Exenatide to Patients in the Cardiac Intensive Care Unit
Abuannadi, M., Kosiborod, M., Riggs, L. A., House, J. A., Hamburg, M. S., Kennedy, K. F., & Marso, S. P. (2012) · Endocrine Practice · doi:10.4158/ep12196.or · Cited by 46
Impact of Diabetes on Postinfarction Heart Failure and Left Ventricular Remodeling
von Bibra, H., & Sutton, M. S. J. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0070-8 · Cited by 44
Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44
Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction
Dokken, B. B., Hilwig, W. R., Teachey, M. K., Panchal, A. R., Hubner, K., Allen, D., Rogers, D. C., & Kern, K. B. (2010) · Resuscitation · doi:10.1016/j.resuscitation.2010.01.031 · Cited by 44
Metabolic Therapy at the Crossroad: How to Optimize Myocardial Substrate Utilization?
Kolwicz, S. C., & Tian, R. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2009.12.005 · Cited by 43
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
Ellenbroek, J. H., Töns, H. A. M., Westerouen van Meeteren, M. J. A., de Graaf, N., Hanegraaf, M. A., Rabelink, T. J., Carlotti, F., & de Koning, E. J. P. (2013) · Diabetologia · doi:10.1007/s00125-013-2957-2 · Cited by 43

Authors: Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P.
Affiliations: Allegheny General Hospital (US)
ORCID: Nikolaidis, Lazaros A.
Mankad, Sunil
Sokos, George G.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-03-02
Volume: 109
Issue: 8
Pages: 962-965
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000120505.91348.58
OpenAlex: W1968315455
Cited by: 901
References: 15
Citations by year: 2026: 9 · 2025: 16 · 2024: 25 · 2023: 18 · 2022: 17 · 2021: 25 · 2020: 27 · 2019: 38 · 2018: 37 · 2017: 46 · 2016: 48 · 2015: 63 · 2014: 71 · 2013: 80 · 2012: 92
FWCI: 16.30
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Pittsburgh Foundation
National Institutes of Health (5r01ag023125-05)
National Institute on Aging (1 R01 AG023125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: glucagon-like peptide-1, acute myocardial infarction, left ventricular dysfunction, primary percutaneous coronary intervention, reperfusion, left ventricular ejection fraction, regional wall motion, incretin-based therapy, glucose-insulin-potassium infusion, systolic dysfunction
MeSH terms: Adult, Aged, Aged, 80 and over, Blood Glucose, Combined Modality Therapy, Glucagon-Like Peptides, Female, Glucagon, Humans, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Pilot Projects, Safety, Stroke Volume, Angioplasty, Balloon, Coronary, Ventricular Function, Left, Treatment Outcome, Diabetes Complications, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks